MAIA Biotechnology, Inc. Common Stock
Key Metrics
Market Snapshot
About
MAIA Biotechnology, Inc. (MAIA) is a clinical-stage biopharmaceutical company based in Chicago, Illinois. It is best known for developing novel, targeted immunotherapies designed to treat various forms of cancer.
The company's primary focus is on its lead drug candidate, Ateganosine. This investigational therapy is a telomere-targeting agent, meaning it is designed to attack cancer cells by interfering with the protective structures at the ends of chromosomes called telomeres. By disrupting these telomeres, the drug aims to stop cancer cell proliferation and induce cell death. MAIA is currently evaluating Ateganosine in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC), a common and often difficult-to-treat form of lung cancer.
As a biopharmaceutical company, MAIA's business model involves advancing its drug candidates through the clinical trial process to demonstrate their safety and efficacy. Success in these trials is a critical step toward potentially seeking regulatory approval from agencies like the U.S. Food and Drug Administration. The company, incorporated in 2018, operates without commercial products currently on the market, relying on investment to fund its research and development activities. Its long-term strategy centers on proving the value of its telomere-targeting platform to address significant unmet medical needs in oncology.